Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease (NCT06989359)
A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
🩺 Plain-English Summary (8th-Grade Level)
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (9 items).
Location: ADARx Clinical Site — Doral, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Hereditary or acquired complement deficiency
- Kidney transplant or renal replacement therapy
- History of solid organ transplant
- Other kidney disease
- History of recurrent invasive infections
- Received complement inhibitor treatments
- Active systemic viral, bacterial, or fungal infection
- Abnormal liver function
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (34 Sites)
Showing the first 25 of 34 sites.
- ADARx Clinical Site — Doral, Florida
- ADARx Clinical Site — Miami, Florida
- ADARx Clinical Site — Pembroke Pines, Florida
- ADARx Clinical Site — Iowa City, Iowa
- ADARx Clinical Site — Shreveport, Louisiana
- ADARx Clinical Site — Shelby, Michigan
- ADARx Clinical Site — Great Neck, New York
- ADARx Clinical Site — Columbus, Ohio
- ADARx Clinical Site — Dakota Dunes, South Dakota
- ADARx Clinical Site — Dallas, Texas
- ADARx Clinical Site — Houston, Texas
- ADARx Clinical Site — Liverpool, New South Wales
- ADARx Clinical Site — Wollongong, New South Wales
- ADARx Clinical Site — Sydney,
- ADARx Clinical Site — Woolloongabba,
- ADARx Clinical Site — Hong Kong,
- ADARx Clinical Site — Shatin,
- ADARx Clinical Site — Bergamo,
- ADARx Clinical Site — Pavia,
- ADARx Clinical Site — Wŏnju, Gangwon-do
- ADARx Clinical Site — Gyeonggi-do, Gurogu
- ADARx Clinical Site — Seoul, Gurogu
- ADARx Clinical Site — Cheonan,
- ADARx Clinical Site — Daegu,
- ADARx Clinical Site — Gyeonggi-do,
📞 Contact the Study Coordinator
Phone: (877) 232-7974
Email: info@adarx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in IgAN
- Study of Ravulizumab in Pediatric Participants With Primary IgAN — Palo Alto, California
Explore by condition: All IgAN clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.